Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests
Nicolas R Barthélemy, Gemma Salvadó, Suzanne E. Schindler, et al.
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 1085-1095
Open Access | Times Cited: 162

Showing 1-25 of 162 citing articles:

Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
Sebastian Palmqvist, Pontus Tideman, Niklas Mattsson, et al.
JAMA (2024) Vol. 332, Iss. 15, pp. 1245-1245
Closed Access | Times Cited: 85
Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
Suzanne E. Schindler, Douglas Galasko, Ana C. Pereira, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 7, pp. 426-439
Open Access | Times Cited: 70
Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Qiuyang Zheng, Xin Wang
Protein & Cell (2024)
Open Access | Times Cited: 24
Alzheimer disease blood biomarkers: considerations for population-level use
Michelle M. Mielke, Nicole R. Fowler
Nature Reviews Neurology (2024) Vol. 20, Iss. 8, pp. 495-504
Closed Access | Times Cited: 24
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment
Shorena Janelidze, Nicolas R. Barthélemy, Gemma Salvadó, et al.
JAMA Neurology (2024) Vol. 81, Iss. 9, pp. 947-947
Closed Access | Times Cited: 21
Head‐to‐head comparison of leading blood tests for Alzheimer's disease pathology
Suzanne E. Schindler, Kellen K. Petersen, Benjamin Saef, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 11, pp. 8074-8096
Open Access | Times Cited: 21
Misfolding and aggregation in neurodegenerative diseases: protein quality control machinery as potential therapeutic clearance pathways
Oliwia Koszła, Przemysław Sołek
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 20
Aggregation-Induced Emission Luminogen: Role in Biopsy for Precision Medicine
Yanhong Duo, Lei Han, Yaoqiang Yang, et al.
Chemical Reviews (2024) Vol. 124, Iss. 20, pp. 11242-11347
Open Access | Times Cited: 18
Blood phosphorylated Tau181 reliably differentiates amyloid‐positive from amyloid‐negative subjects in the Alzheimer's disease continuum: A systematic review and meta‐analysis
Annibale Antonioni, Emanuela Maria Raho, Lamberto Manzoli, et al.
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 5
Lecanemab approval in EU: what should we be ready for?– the EANM perspective
Igor Yakushev, Antoine Verger, Matthias Brendel, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2025)
Open Access | Times Cited: 2
Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use
Michael Schöll, Agathe Vrillon, Takeshi Ikeuchi, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100056-100056
Open Access | Times Cited: 2
Plasma p‐tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10‐year window
Yara Yakoub, Fernándo González‐Ortiz, Nicholas J. Ashton, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 2
Open Access | Times Cited: 2
Donanemab: Appropriate use recommendations
G D Rabinovici, D. J. Selkoe, Suzanne E. Schindler, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100150-100150
Open Access | Times Cited: 2
Tracking neuroinflammatory biomarkers in Alzheimer’s disease: a strategy for individualized therapeutic approaches?
Simone Lista, Bruno P. Imbimbo, Margherita Grasso, et al.
Journal of Neuroinflammation (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 15
Pathogenesis, Diagnostics, and Therapeutics for Alzheimer's Disease: Breaking the Memory Barrier
Pushpa Tryphena Kamatham, Rashi K. Shukla, Dharmendra Kumar Khatri, et al.
Ageing Research Reviews (2024) Vol. 101, pp. 102481-102481
Open Access | Times Cited: 14
Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease
Michael Schöll, Inge M.W. Verberk, Marta del Campo, et al.
The Lancet Healthy Longevity (2024) Vol. 5, Iss. 10, pp. 100630-100630
Open Access | Times Cited: 13
Alzheimer’s disease biomarkers and their current use in clinical research and practice
T. Hunter, Luís E. Santos, Fernanda Tovar‐Moll, et al.
Molecular Psychiatry (2024)
Closed Access | Times Cited: 12
Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability
Joseph Therriault, Shorena Janelidze, Andréa Lessa Benedet, et al.
Nature Aging (2024) Vol. 4, Iss. 11, pp. 1529-1537
Open Access | Times Cited: 12
Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment
Sylvain Lehmann, Susanna Schraen‐Maschke, Jean‐Sébastien Vidal, et al.
Journal of Neurology Neurosurgery & Psychiatry (2024) Vol. 95, Iss. 11, pp. 1046-1053
Open Access | Times Cited: 11
Longitudinal plasma phosphorylated‐tau217 and other related biomarkers in a non‐demented Alzheimer's risk‐enhanced sample
Lianlian Du, Rebecca E. Langhough, Rachael E. Wilson, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 9, pp. 6183-6204
Open Access | Times Cited: 10
Electrochemical Biosensor for Point-of-Care Testing of Low-Abundance Biomarkers of Neurological Diseases
Ziyue Huang, Lei Zhang, Yanzhi Dou, et al.
Analytical Chemistry (2024) Vol. 96, Iss. 25, pp. 10332-10340
Closed Access | Times Cited: 9
Advances in blood biomarkers for Alzheimer disease (AD): A review
Araya Dimtsu Assfaw, Suzanne E. Schindler, John C. Morris
The Kaohsiung Journal of Medical Sciences (2024) Vol. 40, Iss. 8, pp. 692-698
Open Access | Times Cited: 9
A clinical perspective on the revised criteria for diagnosis and staging of Alzheimer’s disease
Oskar Hansson, Clifford R. Jack
Nature Aging (2024) Vol. 4, Iss. 8, pp. 1029-1031
Closed Access | Times Cited: 9
Accuracy and clinical applicability of plasma tau 181 and 217 for Alzheimer’s disease diagnosis in a memory clinic cohort
Jordi Sarto, Diana Esteller-Gauxax, Núria Guillén, et al.
Journal of Neurology (2025) Vol. 272, Iss. 2
Closed Access | Times Cited: 1
Plasma p‐tau217 and p‐tau217/Aβ1‐42 are effective biomarkers for identifying CSF‐ and PET imaging‐diagnosed Alzheimer's disease: Insights for research and clinical practice
Xiaomei Zhong, Qiang Wang, Mingfeng Yang, et al.
Alzheimer s & Dementia (2025)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top